27 results on '"Macielag, Mark"'
Search Results
2. A Long-Acting PYY3–36 Analog Mediates Robust Anorectic Efficacy with Minimal Emesis in Nonhuman Primates
3. Injectable Diabetes Treatments Targeting Glucose Regulation and Satiety Pathways
4. Discovery of Potent and Orally Bioavailable Pyridine N-Oxide-Based Factor XIa Inhibitors through Exploiting Nonclassical Interactions
5. Discovery and Optimization of 7-Alkylidenyltetrahydroindazole-Based Acylsulfonamide EP3 Antagonists
6. Erratum to “Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists” [Bioorg. Med. Chem. Lett. 47 (2021) 128172]
7. Optimization of physicochemical properties of pyridone-based EP3 receptor antagonists
8. Discovery of a novel series of guanidinebenzoates as gut-restricted enteropeptidase and trypsin dual inhibitors for the treatment of metabolic syndrome
9. The discovery of azetidine-piperazine di-amides as potent, selective and reversible monoacylglycerol lipase (MAGL) inhibitors
10. The discovery of diazetidinyl diamides as potent and reversible inhibitors of monoacylglycerol lipase (MAGL)
11. Discovery of a Novel Series of Pyridone-Based EP3 Antagonists for the Treatment of Type 2 Diabetes
12. Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB1R Inverse Agonists
13. GPR120 agonists for the treatment of diabetes: a patent review (2014 present)
14. Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase Inhibitor
15. Discovery and Optimization of 7-Alkylidenyl-tetra-hydro-indazole-Based Acylsulfonamide EP3 Antagonists.
16. Discovery of PEGylated 6‑Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB1R Inverse Agonists.
17. Tetrahydropyrazolo[4,3-c]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists
18. Tetrahydroindazole derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists
19. 6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity
20. Therapeutic Potential of EP3 Receptor Antagonists for Treatment of Noninsulin Dependent Diabetes Mellitus across Multiple Preclinical Models
21. Discovery of an Isothiazole-Based Phenylpropanoic Acid GPR120 Agonist as a Development Candidate for Type 2 Diabetes
22. 7-(4-Alkylidenylpiperidinyl)-quinolone bacterial topoisomerase inhibitors
23. Tetrahydropyrazolo[4,3- c ]pyridine derivatives as potent and peripherally selective cannabinoid-1 (CB1) receptor inverse agonists
24. 6‑Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB1) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity.
25. Discovery of PEGylated 6-Benzhydryl-4-amino-quinazolines as Peripherally Restricted CB 1 R Inverse Agonists.
26. Pharmacologic Characterization of JNJ-42226314, [1-(4-Fluorophenyl)indol-5-yl]-[3-[4-(thiazole-2-carbonyl)piperazin-1-yl]azetidin-1-yl]methanone, a Reversible, Selective, and Potent Monoacylglycerol Lipase Inhibitor.
27. 6-Benzhydryl-4-amino-quinolin-2-ones as Potent Cannabinoid Type 1 (CB 1 ) Receptor Inverse Agonists and Chemical Modifications for Peripheral Selectivity.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.